106 related articles for article (PubMed ID: 35461118)
1. Pain severity and pain interference during major depressive episodes treated with escitalopram and aripiprazole adjunctive therapy: a CAN-BIND-1 report.
Diep C; Rosenek N; Khoo Y; Gandhi W; van Reekum CM; Ravindran AV; Ladha KS; Frey BN; Milev RV; Rotzinger S; Lam RW; Kennedy SH; Lou W; Salomons T; Bhat V
Psychiatry Res; 2022 Jun; 312():114557. PubMed ID: 35461118
[TBL] [Abstract][Full Text] [Related]
2. Symptomatic and Functional Outcomes and Early Prediction of Response to Escitalopram Monotherapy and Sequential Adjunctive Aripiprazole Therapy in Patients With Major Depressive Disorder: A CAN-BIND-1 Report.
Kennedy SH; Lam RW; Rotzinger S; Milev RV; Blier P; Downar J; Evans KR; Farzan F; Foster JA; Frey BN; Giacobbe P; Hall GB; Harkness KL; Hassel S; Ismail Z; Leri F; McInerney S; MacQueen GM; Minuzzi L; Müller DJ; Parikh SV; Placenza FM; Quilty LC; Ravindran AV; Sassi RB; Soares CN; Strother SC; Turecki G; Vaccarino AL; Vila-Rodriguez F; Yu J; Uher R;
J Clin Psychiatry; 2019 Feb; 80(2):. PubMed ID: 30840787
[TBL] [Abstract][Full Text] [Related]
3. Cognitive Outcomes with Sequential Escitalopram Monotherapy and Adjunctive Aripiprazole Treatment in Major Depressive Disorder: A Canadian Biomarker Integration Network in Depression (CAN-BIND-1) Report.
Chakrabarty T; McInerney SJ; Torres IJ; Frey BN; Milev RV; Müller DJ; Rotzinger S; Kennedy SH; Lam RW;
CNS Drugs; 2021 Mar; 35(3):291-304. PubMed ID: 33683582
[TBL] [Abstract][Full Text] [Related]
4. Symptom Dimension of Interest-Activity Indicates Need for Aripiprazole Augmentation of Escitalopram in Major Depressive Disorder: A CAN-BIND-1 Report.
Uher R; Frey BN; Quilty LC; Rotzinger S; Blier P; Foster JA; Müller DJ; Ravindran AV; Soares CN; Turecki G; Parikh SV; Milev R; MacQueen G; Lam RW; Kennedy SH;
J Clin Psychiatry; 2020 Jun; 81(4):. PubMed ID: 32558407
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
[TBL] [Abstract][Full Text] [Related]
6. An investigation of cortical thickness and antidepressant response in major depressive disorder: A CAN-BIND study report.
Suh JS; Minuzzi L; Raamana PR; Davis A; Hall GB; Harris J; Hassel S; Zamyadi M; Arnott SR; Alders GL; Sassi RB; Milev R; Lam RW; MacQueen GM; Strother SC; Kennedy SH; Frey BN
Neuroimage Clin; 2020; 25():102178. PubMed ID: 32036277
[TBL] [Abstract][Full Text] [Related]
7. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
[TBL] [Abstract][Full Text] [Related]
9. Effect of aripiprazole on promoting cognitive function and enhancing clinical efficacy in patients with first-episode depression on escitalopram: A randomized controlled trial.
Wang Y; Lu Z; Xun G
J Affect Disord; 2024 Jan; 344():159-168. PubMed ID: 37827257
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Quality of Life Improvement with Escitalopram and Adjunctive Aripiprazole in Patients with Major Depressive Disorder: A CAN-BIND Study Report.
Morton E; Bhat V; Giacobbe P; Lou W; Michalak EE; McInerney S; Chakrabarty T; Frey BN; Milev RV; Müller DJ; Parikh SV; Rotzinger S; Kennedy SH; Lam RW;
CNS Drugs; 2021 Apr; 35(4):439-450. PubMed ID: 33860922
[TBL] [Abstract][Full Text] [Related]
11. Randomized, double-blind comparison of aripiprazole/sertraline combination and placebo/sertraline combination in patients with major depressive disorder.
Kamijima K; Kimura M; Kuwahara K; Kitayama Y; Tadori Y
Psychiatry Clin Neurosci; 2018 Aug; 72(8):591-601. PubMed ID: 29660207
[TBL] [Abstract][Full Text] [Related]
12. Males and females differ in reported sexual functioning with escitalopram treatment for major depressive disorder: A CAN-BIND-1 study report.
Espinola CW; Khoo Y; Parmar R; Demchenko I; Frey BN; Milev RV; Ravindran AV; Parikh SV; Ho K; Rotzinger S; Lou W; Lam RW; Kennedy SH; Bhat V
J Psychopharmacol; 2022 May; 36(5):604-613. PubMed ID: 35546043
[TBL] [Abstract][Full Text] [Related]
13. Impacts on Quality of Life with Escitalopram Monotherapy and Aripiprazole Augmentation in Patients with Major Depressive Disorder: A CAN-BIND Report.
Morton E; Bhat V; Giacobbe P; Lou W; Michalak EE; Chakrabarty T; Frey BN; Milev RV; Müller DJ; Parikh SV; Rotzinger S; Kennedy SH; Lam RW;
Pharmacopsychiatry; 2021 Sep; 54(5):225-231. PubMed ID: 33652477
[TBL] [Abstract][Full Text] [Related]
14. Aripiprazole augmentation in major depressive disorder: a double-blind, placebo-controlled study in patients with inadequate response to antidepressants.
Berman RM; Fava M; Thase ME; Trivedi MH; Swanink R; McQuade RD; Carson WH; Adson D; Taylor L; Hazel J; Marcus RN
CNS Spectr; 2009 Apr; 14(4):197-206. PubMed ID: 19407731
[TBL] [Abstract][Full Text] [Related]
15. Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram.
Soares CN; Thase ME; Clayton A; Guico-Pabia CJ; Focht K; Jiang Q; Kornstein SG; Ninan PT; Kane CP
CNS Drugs; 2011 Mar; 25(3):227-38. PubMed ID: 21323394
[TBL] [Abstract][Full Text] [Related]
16. Pretreatment anxious depression as a predictor of side effect frequency and severity in escitalopram and aripiprazole adjunctive therapy.
Espinola CW; Khoo Y; Parmar R; Demchenko I; Frey BN; Milev RV; Ravindran AV; Parikh SV; Ho K; Rotzinger S; Lou W; Lam RW; Kennedy SH; Bhat V;
Brain Behav; 2022 May; 12(5):e2555. PubMed ID: 35333448
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy.
Nelson JC; Thase ME; Bellocchio EE; Rollin LM; Eudicone JM; McQuade RD; Marcus RN; Berman RM; Baker RA
Int Clin Psychopharmacol; 2012 May; 27(3):125-33. PubMed ID: 22466058
[TBL] [Abstract][Full Text] [Related]
18. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
[TBL] [Abstract][Full Text] [Related]
19. Global benefit-risk analysis of adjunctive aripiprazole in the treatment of patients with major depressive disorder.
Wisniewski SR; Chen CC; Kim E; Kan HJ; Guo Z; Carlson BX; Tran QV; Pikalov A
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):965-72. PubMed ID: 19662630
[TBL] [Abstract][Full Text] [Related]
20. Adjunctive aripiprazole therapy with escitalopram in patients with co-morbid major depressive disorder and alcohol dependence: clinical and neuroimaging evidence.
Han DH; Kim SM; Choi JE; Min KJ; Renshaw PF
J Psychopharmacol; 2013 Mar; 27(3):282-91. PubMed ID: 23325372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]